Press Releases TG Therapeutics, Inc.

Equities

TGTX

US88322Q1085

Market Closed - Nasdaq Other stock markets 21:00:00 10/05/2024 BST			5-day change	1st Jan Change
16.62 ^USD	-1.77%		+2.66%	-2.69%

05-01	Wall Street Set to Open Lower Ahead of Fed Rate Decision; Private Employment Figures Top Forecasts	MT
05-01	Transcript : TG Therapeutics, Inc., Q1 2024 Earnings Call, May 01, 2024

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

TG Therapeutics: Q1 Earnings Snapshot	05-01	AQ
TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results	05-01	AQ
TG Therapeutics to Host Conference Call on First Quarter 2024 Financial Results and Business Update	04-30	AQ
TG Therapeutics Announces Additional Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting	04-19	AQ
TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting	04-18	AQ
TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis	04-18	AQ
TG Therapeutics Announces Presentation of Data for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting	04-16	AQ
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting	04-15	AQ
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting	03-08	AQ
TG Therapeutics Announces Presentation of Data for BRIUMVI in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum	03-04	AQ
TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum	03-01	AQ
TG Therapeutics: Q4 Earnings Snapshot	02-28	AQ
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results	02-28	AQ
TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI® (ublituximab-xiiy)	02-27	AQ
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2023 Financial Results and Business Update	02-26	AQ
TG Therapeutics Announces European Launch of BRIUMVI® (ublituximab-xiiy)	02-26	AQ
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2023 Financial Results and Business Update	02-23	AQ
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum	02-21	AQ
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum	02-20	AQ
TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision's Allogeneic CD19 CAR T Cell Therapy	01-10	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases TG Therapeutics, Inc.

Equities

TGTX

US88322Q1085

Press Releases

Filters